Vol 8, Supplement 2 (March 28, 2019): Translational Cancer Research

Editorial

Third line scenario in advanced non-small cell lung cancer: is the anti-angiogenetic strategy the only actor up to now?

Caterina Mecca, Valentina Bertaglia, Silvia Novello

PDF Pages: S79-S83 Full Text (5040) Open Access

Postmastectomy radiation therapy in women with T1–T2 tumors and 1 to 3 positive lymph nodes: analysis of the breast international group 02-98 trial

Fabiana Gregucci, Maria Carmen De Santis, Laura Lozza, Alba Fiorentino

PDF Pages: S84-S86 Full Text (1857) COI Form Open Access

Anti-GD2 CAR T cells could prove transformative for H3-K27M+ diffuse midline gliomas

Koichi Furukawa, Yuhsuke Ohmi, Keiko Furukawa

PDF Pages: S87-S93 Full Text (2294) COI Form Open Access

The combination of bevacizumab with chemotherapy is more beneficial in the metastatic setting rather than in the adjuvant setting for the treatment of HER2-negative breast cancer—a commentary on the E5103 randomized phase III clinical study

Giandomenico Roviello, Daniele Generali, Navid Sobhani

PDF Pages: S94-S96 Full Text (1454) COI Form Open Access

Value of magnetic resonance imaging in predicting BRAF mutation in craniopharyngiomas

Mario Giordano, Ismail Zaed

PDF Pages: S97-S98 Full Text (1283) COI Form Open Access

A new paradox for pCR in BRCA mutation carriers

Konstantinos Rounis, Dimitrios Mavroudis

PDF Pages: S99-S102 Full Text (1970) COI Form Open Access

Atezolizumab plus platinum-based regimen and bevacizumab: is it time to consider immunotherapy in a concurrent approach for lung cancer?

Andrea Bianco, Susan F. M. Campbell

PDF Pages: S103-S105 Full Text (1968) COI Form Open Access

CircNT5E/miR-422a: a new circRNA-based ceRNA network in glioblastoma

Deborah Morena, Francesca Picca, Riccardo Taulli

PDF Pages: S106-S109 Full Text (1597) COI Form Open Access

Whether adjuvant radiotherapy is desired for postmastectomy patients with T1–T2 tumors and 1–3 positive axillary lymph nodes who received modern systemic therapy?

Shih-Fan Lai, Chiun-Sheng Huang, Sung-Hsin Kuo

PDF Pages: S110-S114 Full Text (1448) COI Form Open Access

Proton beam radiosurgery: early clinical results

Janet Leon, Jennifer Peterson, Austin Hadley, Laura Vallow, Daniel M. Trifiletti

PDF Pages: S115-S117 Full Text (1762) COI Form Open Access

Impact of breast surgery in de novo stage IV breast cancer

Tadahiko Shien

PDF Pages: S118-S119 Full Text (1755) COI Form Open Access

Evolving development of multi-parametric normal tissue complication probability model for liver radiotherapy

Chiao-Ling Tsai, Jason Chia-Hsien Cheng

PDF Pages: S120-S123 Full Text (1387) COI Form Open Access

Development and validation of a polygenic hazard score for aggressive prostate cancer identification

Nihal E. Mohamed, Ashutosh K. Tewari, Kamlesh K. Yadav

PDF Pages: S124-S125 Full Text (1192) COI Form Open Access

Circular RNA as a prospective molecular tool for the study of neuroprotection in cerebral ischemia

Svetlana A. Limborska, Ivan B. Filippenkov

PDF Pages: S126-S129 Full Text (1730) COI Form Open Access

The role of avelumab in advanced urothelial carcinoma in the context of a dynamic treatment landscape

Vadim S. Koshkin, Arnab Basu, Petros Grivas

PDF Pages: S130-S132 Full Text (1255) Open Access

ARID1A: guardian of normal pancreatic ducts

Karla J. Castellanos, Paul J. Grippo

PDF Pages: S133-S134 Full Text (1329) COI Form Open Access

Twist1 activated circRNA-10720 is a new player in hepatocellular carcinoma metastasis

Alfons Navarro

PDF Pages: S135-S140 Full Text (1446) COI Form Open Access

Prospects for cost-effective lung cancer screening using risk calculators

Marianne Weber, Annette McWilliams, Karen Canfell

PDF Pages: S141-S144 Full Text (2416) Open Access

Second-line avelumab in platinum-treated non-small cell lung cancer patients: comment on the JAVELIN Lung 200 clinical trial

Danilo Rocco, Luigi Della Gravara, Umberto Malapelle, Giancarlo Troncone, Cesare Gridelli

PDF Pages: S145-S148 Full Text (2586) COI Form Open Access

Metastasis suppression and enhancement of anti-tumour immunity by targeting the FSTL1-DIP2A axis

Gopinath M. Sundaram, Shan Quah, Prabha Sampath

PDF Pages: S149-S151 Full Text (1565) COI Form Open Access

Editorial on the integrated multidisciplinary algorithm for the management of spinal metastases

Wen Jie Choy, Kevin Phan, Ralph J. Mobbs

PDF Pages: S152-S155 Full Text (2367) COI Form Open Access

The time has come to pull renal cancer’s sweet tooth

Adam Kinnaird, Evangelos D. Michelakis

PDF Pages: S156-S161 Full Text (2004) COI Form Open Access

Bevacizumab in recurrent glioblastoma

Nina L. Martinez, Jon Glass, Wenyin Shi

PDF Pages: S162-S163 Full Text (1681) COI Form Open Access

The updated AJCC/TNM staging system (8^th edition) for oral tongue cancer

Kyubo Kim, Dong Jin Lee

PDF Pages: S164-S166 Full Text (13397) COI Form Open Access

(R)-2-hydroxyglutarate drives immune quiescence in the tumor microenvironment of IDH-mutant gliomas

Leland G. Richardson, Bryan D. Choi, William T. Curry

PDF Pages: S167-S170 Full Text (3463) COI Form Open Access

Oligometastatic prostate cancer: is it worth targeting the tip of the iceberg?

Stéphane Supiot, Caroline Rousseau

PDF Pages: S171-S175 Full Text (3146) Open Access

Neoadjuvant cisplatin-based chemotherapy in “primary” and “secondary” muscle-invasive bladder cancer—is it a surrogate for molecular subtypes?

Tibor Szarvas, Csilla Olah, Henning Reis

PDF Pages: S176-S179 Full Text (2038) COI Form Open Access

Role of pelvic lymph node dissection in bladder cancer: is it better to do more?

Anthony Dat, Shomik Sengupta

PDF Pages: S180-S182 Full Text (1602) COI Form Open Access

Squaring the circle: sponging microRNAs in gastric cancer

Steven G. Gray

PDF Pages: S183-S187 Full Text (1039) COI Form Open Access

Treatment intensity in locoregionally advanced head and neck cancer: recent investigation leads to new questions

James A. Bonner, Drexell H. Boggs

PDF Pages: S188-S194 Full Text (1986) Open Access

Circular RNA YAP1: a new player in gastric cancer

Lorena Verduci, Giovanni Blandino

PDF Pages: S195-S197 Full Text (1698) COI Form Open Access

Multimodal action of ONECUT2 in driving neuroendocrine prostate cancer

Salma Kaochar, Nicholas Mitsiades

PDF Pages: S198-S203 Full Text (4168) COI Form Open Access

Editorial Commentary

Massively parallel sequencing of urinary DNA—the dawn of non-invasive bladder cancer detection and surveillance?

Douglas G. Ward, Richard T. Bryan

PDF Pages: S204-S207 Full Text (1935) COI Form Open Access

Re: Comparison of immediate vs. deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical trial

Andrea Minervini, Andrea Mari, Fabrizio Di Maida, Riccardo Campi, Marco Carini, Alberto Lapini

PDF Pages: S208-S210 Full Text (1794) COI Form Open Access

The control of tumor progression by circular RNAs: novel prognostic and therapeutic insights resulting from the analysis of the circAGO2/human antigen R complex

Simona Pellecchia, Cristina Quintavalle, Pierlorenzo Pallante

PDF Pages: S211-S215 Full Text (1491) COI Form Open Access